Who
Sheila Gujrathi
Director
Company insider
Files Form 4 as: Director, Processa Pharmaceuticals; Director, Ventyx Biosciences; Director, Janux Therapeutics; Director, Turning Point Therapeutics; President & CEO, Gossamer Bio; Director, Five Prime Therapeutics; Chief Medical Officer, Receptos.
In numbers
- Trades disclosed
- 67
- Buys
- 2
- Sells
- 3
- Bought
- $468K
- Sold
- $8.5M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 14 May 2013
- Last trade
- 28 Jul 2026
- Last filed
- 30 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 30 Jul 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,811.877 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,311.279 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,811.88 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,311.28 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx BiosciencesBiotechnology | SEC FORM 4 Code D | —130,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —33,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —33,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —80,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —662,369 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —277,941 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —21,825 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —15,937 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —80,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —662,369 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —277,941 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —21,825 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,937 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciences | SEC FORM 4 Code D | —130,000 | filing |
News
Chardan Capital Begins Coverage on Gossamer Bio (NASDAQ:GOSS)GOSS · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Sheila Gujrathi; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.